Merck & Co. (MRK) Q1 2025 Earnings
Merck & Co. reported Q1 2025 revenue of $15.5B (-1.6% YoY), beat analyst consensus of $15.3B by $190.1M. Diluted EPS came in at $2.22 (+7.2% YoY), beat the $2.13 consensus by $0.09. Merck & Co. reports across 2 business segments, led by Pharmaceutical and Animal Health.
Financial Snapshot
Trailing eight quarters through Q1 2025
Q1 2025 Earnings FAQ
Common questions about Merck & Co.'s Q1 2025 earnings report.
Merck & Co. (MRK) reported Q1 2025 earnings on April 24, 2025 before market open.
Merck & Co. reported revenue of $15.5B and diluted EPS of $2.22 for Q1 2025.
Revenue beat the consensus estimate of $15.3B by $190.1M. EPS beat the consensus estimate of $2.13 by $0.09.
Compared to the same quarter a year prior, revenue declined 1.6% from $15.8B a year earlier and diluted EPS grew 7.2% from $2.07.
You can read the 10-Q periodic report (0001628280-25-021834) directly on SEC EDGAR. The filing index links above go to sec.gov.